Abstract. For more than 40 years, practitioners have sought to improve all aspects of commercial bovine embryo transfer. The development of new technologies for this industry has been substantial, with recent focus on cryopreservation techniques and the in vitro production of embryos fertilised with sexed spermatozoa. When these and other new technologies are developed, the following questions remain: (1) is said technology regulated or does it require licensing; and (2) is it applicable and, if so, is it financially feasible? Computer access to published research and the advancement of data software programs conducive to the industry for data procurement have been essential for helping practitioners answer these questions by enhancing their ability to analyse and apply data. The focus of the present paper is to aid commercial embryo transfer practitioners in determining new technologies that are available and whether they can be implemented effectively, benefiting their programs.
Introduction
In the early days of the commercial embryo transfer (ET) industry, progress was slow due to the business being very lucrative, information of methodologies secretive and information on new developments slow to disseminate. However, with ET practitioners being 'results oriented', they have moved to work more with science and technology, aiming to improve all aspects of mammalian ET since its inception (Heape 1891) . Beginning in 1972, the bovine ET industry was revolutionised with new improvements in semen cryopreservation (Berndtson and Foote 1972; D'Alleinne and Merilan 1977) , hormone treatments for superovulation and oestrus synchronisation , artificial insemination (Hardin et al. 1980 ) and non-surgical embryo collections (Betteridge 1977; Sreenan 1978) . During this expansion, researchers continued to present new data on all areas within the industry, including, but not limited to, embryo cryopreservation (Dobrinsky 2002; Vajta and Kuwayama 2006) , IVF (Brackett et al. 1980; Looney et al. 1994 ) and recipient synchronisation (Looney et al. 2006) . However, the key to using these new technologies in practice is the ability to analyse one's own data simply, objectively and concisely. With International Embryo Transfer Society (IETS) guidelines, practitioners have access to formatted collection, transfer and freeze forms that are an important step in data collection. In addition, advances in computer software have enabled clinicians to keep real-time records in the field or network data within their own company (Oliver et al. 2005) . The purpose of the present paper is threefold:
(1) giving direction as to how to procure and analyse data from within a practitioner's own business; (2) knowing where to find new technology; and (3) knowing when to apply this new technology, specifically IVF and vitrification, in the clinical setting.
Data procurement: getting started
The key for any successful business is the ability to collect, analyse and, in particular, use data. Microsoft (Bellevue, WA, USA) Excel is a computer software program that is used successfully for data collection throughout many industries (Delboy 1994; Kambhampati 2007) . Quite simply, primary areas for data collection are identified and added to the Excel spreadsheet. Some of these areas may include, but are not limited to, the following: donor and sire reproductive health and history, type of superovulation regimen, oestradiol/progesterone (Bó et al. 2002) , embryo grade, size of the corpus luteum (1, large; 2 or 3, small), embryo transfer ease (1, good; 2 or 3, poor), collection, transfer data and pregnancy results. Analysis of these types of data allows the practitioner to determine how the factors under consideration affect results. Practitioners that are results oriented can improve their success rates faster than others who do not use these data. Much of the above information is formatted concisely on the IETS forms. Using Excel's format, columns of interest can be analysed by adding and establishing means for the evaluation or summarising of data for reports. For further statistical analysis, other software packages, such as JMP In 5.1 software (SAS Institute, Cary, NC, USA), SigmaStat or SigmaPlot (Systat Software Inc., Chicago, IL, USA; Kornbrot 2000) can be used with this type of spreadsheet, allowing data to be submitted to other types of tests (e.g. Student's t-test, ANOVA or Chi-squared analysis) to determine significant differences and variations within treatment columns. Results may indicate a 'non-significant difference' between treatments or within a treatment group but, to the practitioner, there may be enough of a difference to explore it further under field conditions. An example of this may be a new freezing protocol that could provide a 7% increase in pregnancy rates. Depending on the statistical power of the study, differences may be non-significant but, to the practitioner, seven more pregnancies out of 100 could be very important, especially if from a genetically valuable donor.
To minimise time spent transferring data from one spreadsheet to another, software companies have worked with practitioners to establish customised software, such as Phoenix software from Minitube of America (Verona, WI, USA) (Walter 1999) . Incorporating software programs in the field will allow the practitioner to create on-site invoicing, certificates of collections transfers and freezing, embryo inventories and to procure data for later analysis. These systems can be networked for real-time home office use and backed up daily, thereby decreasing the amount of paper and storage needed for filing. However, these systems can be quite expensive (US$2000 to upwards of US$100 000) and may not be economically feasible. Free software can be downloaded from the Internet (Oliver et al. 2005; Pryor et al. 2009 ), but computer random access memory (RAM) and software capabilities (Windows XP, Vista or Mac) must be considered before downloading any information.
Research resources
For the practitioner, being affiliated with embryo transfer societies such as the American Embryo Transfer Association (AETA), IETS, Canadian Embryo Transfer Association (CETA), Brazilian Society for Embryo Technology (SBTE), European Embryo Transfer Association (AETE), Australian Embryo Transfer Society (AETS) and others, is a valuable tool to access new technology. Meetings of these societies promote the exchange of new science and technological advances within the ET industry. Product vendors are usually invited to these meetings and, in some cases, will supply their product(s) free for testing. In addition to bringing colleagues together once a year, these meetings can establish new relationships and potential partnerships with academia.
Access to both public and university libraries is another valuable research information tool. At universities, searches for journal articles within the library and e-journals are often made available to the public. Most research publications have the authors' email addresses or links to their universities, making personal communication possible. In many instances, practitioners can collaborate with university graduate-training programs, partially or fully supporting a project financially or 'in-kind', and then using the new information to benefit their practice and/or the industry overall.
Other sources of new technology can be found on the Internet through search engines such as PubMed (http:// www.ncbi.nlm.nih.gov/pubmed/, accessed September 2009) or Google Scholar (http://www.google.com, accessed September 2009). Subscribers to particular journals (e.g. Theriogenology, Reproduction, Fertility and Development, Journal of Animal Science, Biology of Reproduction) are charged an annual fee but, through PubMed, abstracts (if available) and some manuscripts are free. Society memberships may include online journal subscription free of charge or at a reduced rate (e.g. membership in the IETS currently includes online access to Reproduction, Fertility and Development), or articles that are not free can be purchased.
Other new technology comes with a price in the way of intellectual property. The United States Patent and Trademark Office (USPTO; http://www.uspto.gov, accessed September 2009) and the World Intellectual Property Organisation (WIPO; http://www.wipo.int/, accessed September 2009) are resources that are crucial in determining the use of a product or procedure. Some patents (even those that are invalid or frivolous) can be expensive if proper guidelines are not followed, but the sites are easy to search and give full disclosure of the applied for or acquired patent.
Practitioners who subscribe to online reproduction forums, such as embryo mail (http://embryomail.net/mailman/listinfo/ em, accessed September 2009) or Tech Talk (ceta@ebi.ca) can post questions or discuss situations that reach thousands of interested colleagues.A response is often received within 24 h. For the authors, these sites have occasionally provided valuable information (when researched) that has circumvented possible problems within the laboratory. Even though these sites are personal correspondence on science/medical or reproductive issues, they occasionally contain literature citations, which allow the reader to evaluate the comments for credibility.
Guidelines and regulations
In the US, the Animal and Plant Health Inspection Services (APHIS) is a government agency that regulates the importation and exportation of animals, animal products (e.g. embryos, semen) and biologicals. Each state (within the US) or country has specific test requirements that must be met before animals or animal products move internationally. For a list of these requirements, readers can log onto the APHIS website at http://www.aphis.usda.gov/ (accessed September 2009).
In vivo-collected embryos to be exported must be processed in accordance with IETS guidelines (Stringfellow 1998) . Briefly, the zona pellucida must be intact and free of adherent material and the embryos must be washed 10 times with a 1 : 100 dilution per wash, and often treated twice with 0.25% trypsin, before cryopreservation (Trachte et al. 1998; Givens and Marley 2008) . This procedure reduces the risk of disease transmission from, but not limited to, bluetongue (Thomas et al. 1983) , bovine spongiform encephalopathy (Wrathall et al. 2002) , Brucella abortus (del Campo et al. 1987) , bovine leucosis virus and bovine herpesvirus-1 (Thibier and Nibart 1987) .
In the US, only licensed veterinarians can write prescriptions for Food and Drug Administration (FDA)-approved drugs. The prescription must document the client and product information and must be signed and dated by the licensed veterinarian. Prescriptions are kept on file and are inspected biannually byAPHIS. In addition, ET practitioners and on-staff licensed veterinarians must be certified through APHIS to be eligible to export embryos and need to be recertified annually to maintain this status.
Applying new technology
In itself, ET is a new technology that continues to progress. A good example is the changes that were made in the 1970s from surgical to non-surgical embryo collections and transfers that revolutionised the ET industry (Baker and Jillella 1978; Rowe et al. 1980) . Other new technologies are constantly being applied to several areas within the cattle industry, including (but not limited to) embryo production (Lonergan 2007) , stem cell research (Oback 2009) , in vivo-and in vitro-produced embryo cryopreservation Vajta and Kuwayama 2006) , vitrification (Lindemans et al. 2004; Horvath and Seidel 2006) , embryo lipolysis (Tominaga et al. 2000) , ultrasound-guided follicular aspirations for in vitro embryo production (IVP; Callesen et al. 1987; van der Schans et al. 1991; Looney et al. 1994 ) and the use of sexed spermatozoa in embryo production (Garner and Seidel 2008) . However, these technologies raise the following questions: (1) which new advancements can benefit my practice; and/or (2) is the product or procedure regulated and, if so, what are these regulations? Probably the most important question asked by a practitioner is, will this be economically feasible for both my practice and clientele? For the sake of time and space, we will focus on two areas of applied technology, namely IVP and vitrification, addressing the aforementioned questions.
Bovine IVP
Briefly, IVP is a procedure by which oocytes are removed from the ovary via transvaginal ultrasound-guided ovum pickup (OPU) or from abattoir-derived ovaries for both commercial (Hasler 1998 ) and research (Pryor et al. 2009 ) purposes. The oocytes recovered can be in vitro matured (IVM) in media containing various concentrations of hormones and serum, subjected to IVF and then in vitro cultured (IVC) for 7 days for either transfer or cryopreservation (Looney et al. 1995; Galli et al. 2003; Chaubal et al. 2006) . Since its inception, the use of IVP in cattle has increased steadily. From 2006 to 2007, the AETA Statistical Committee indicated that the production of IVP embryos doubled (from 1868 to 3504 for beef and from 460 to 985 for dairy). In Brazil, the number of IVP embryos increased from 401 in 2000 to a total of 128 914 in 2005, accounting for 48.5% of the world's bovine IVP embryos (Viana and Camargo 2007) . Research on follicle dynamics and dominant follicle removal for IVF technology has resulted in improvements in superovulation ). In addition, inexpensive IVP embryos from abattoir-derived ovaries can be used to evaluate media or cryopreservation techniques. With research indicating the potential value of IVP, the next step is to determine applications that will best serve practitioners' specific needs.
Application of IVP
The application of IVP in prepubertal heifers can result in shortened generation intervals (Looney et al. 1995; Armstrong et al. 1997) in that offspring can be produced before the heifer is old enough for conventional ET. Opinions differ regarding the optimum age of when OPU should be conducted initially. Researchers have collected oocytes from heifers as young as 10-12 weeks to >180 days of age with low to moderate embryo production and calving success rates (Looney et al. 1995; Duby et al. 1996; Armstrong et al. 1997) . With younger heifers, consideration must be given to the diameter of the rectum, which can make transvaginal retrievals difficult for practitioners with large forearms. However, researchers have shown that it is possible to do OPU in young calves without transrectal manipulation of the ovaries (Brogliatti and Adams 1996) .
Application of OPU to clinically infertile ET donors (i.e. those not producing viable embryos due either to oviduct or uterine problems) could potentially save valuable genetics. These donors could be collected as often as twice weekly, with or without superstimulation (Gibbons et al. 1994; Bungartz et al. 1995) . In 1999, Bousquet et al. (1999) demonstrated that IVP in Holstein cattle could result in a higher mean number of embryos per collection than in vivo-production of embryos (4.7 ± 3.7 v. 4.3 ± 4.0, respectively). Their group also reported 3.8 pregnancies per collection following biopsy of IVP embryos for sexing compared with 1.2 for in vivo-produced embryos (Bousquet et al. 1999) , a high mark for most practitioners to emulate. AETA (2007) reported 13 000 IVP bovine embryos from 4489 collections, yielding a mean of 2.9 embryos per collection v. a combined average (beef 6.6 and dairy 5.5) of 6.0 embryos per in vivo collection. Factoring in the above numbers, a donor collected by OPU once a week for 12 weeks could produce a total of 34.7 embryos compared with three in vivo embryo collections in 6 months (the usual average at Ovagenix before natural breeding) yielding 18.0 embryos, providing the practitioner with nearly twice as many embryos in half the time. In addition, IVP facilitates the use of sexed spermatozoa, which is reported to have a purity of 90% but costs more per unit, contains lower concentrations of spermatozoa per unit (2.1-5.0 × 10 6 ) and has been shown to have a lower conception rate in cows than conventional semen . The use of sexed spermatozoa in IVP would allow one unit to fertilise more donor oocytes than in AI, producing more embryos (Garner and Seidel 2008) . Commercial firms, such as American Breeders Service Global (Deforest, WI, USA), Sexing Technologies (Navasota, TX, USA), Genex (Guelph, Canada) or Boviteq (St Hyacinthe, Quebec, Canada), are suppliers of sex-sorted spermatozoa.
Furthermore, IVP is an excellent research tool for testing media and other assorted handling and/or cryopreservation techniques. We estimate that the cost of producing one IVP embryo (including supplies, media, labour and oocyte procurement) is US$20.00, compared with US$83.00 for an in vivo-produced embryo, which excludes any donor/sire genetic value. Therefore, IVP data can aid the practitioner in determining whether the procedure/media was effective for increasing embryo survivability and development, which could help render a decision whether to further its use on in vivo-produced embryos.
Occasionally, technological advances do not come without shortcomings. One disadvantage to IVP is the high cost of equipment, which can be as much as US$100,000. This may be overcome by using satellite IVP laboratories, which could lower equipment costs by as much as 75%. Cumulus-oocyte complexes can be shipped overnight in maturation medium, fertilised, cultured and then returned 7 days after IVF for transfer. Another current disadvantage of this technology is the extra time needed to train practitioners to perform OPU. Several commercial firms offer training programs in IVP, cryopreservation and ET. Other problems that can occur with IVP are lower pregnancy rates (Kruip and den Daas 1997) , especially following cryopreservation (Leibo and Loskutoff 1993; ), large calves (Numabe et al. 2000) and hardening of the zona pellucida, which may be overcome if the practitioner has access to a microscope-mounted laser . These areas are being investigated extensively, but all must be considered by the practitioner when considering the use of IVP in their program.
Vitrification
The ability to produce and implement viable IVP embryos in a commercial program is only half the equation. The other half is being able to cryopreserve IVP embryos when synchronised recipients are not available. It has been well documented that IVP embryos do not survive cryopreservation as well as their in vivo counterparts (Hasler 1998) . One reason for this is the elevated intracellular lipid levels (Dobrinsky 1996; Abe et al. 2002) . In addition, Bos indicus IVP embryos have a higher content of intracellular lipids than Bos taurus embryos, increasing their sensitivity to conventional freezing methods (Murakami et al. 1998; Ballard et al. 2008) . Researchers are addressing these issues in several ways: (1) nutritionally, by lowering dietary fat; (2) mechanically, through the removal of lipid droplets by micromanipulation; and (3) chemically, using lipolytic agents (Murakami et al. 1998; Adamiak et al. 2005; Ballard et al. 2008; Barcelo-Fimbres and Seidel 2009; Pryor et al. 2009 ). Another approach is the use of a different cryopreservation technique that is more appropriate for hard-to-freeze embryos (i.e. vitrification). Since the inception of vitrification (i.e. rapid cooling in high concentrations of cryoprotectants that solidify without the formation of ice crystals), there has been a concentrated effort to determine the optimal concentrations of cryoprotectants, carriers and warming rates etc. for different types of embryos (Rall and Fahy 1985) . Recently, Bioniche Animal Health (Pullman, WA, USA) has commercialised a vitrification kit for bovine and equine embryos. Briefly, bovine embryos are placed in VS1 solution for 3 min and then in 15 µL VS2 for 45 s before being loaded into sterile 0.25-mL straws using the provided diluent with VS2 separated by air columns and then vitrified in liquid nitrogen vapour (the straw is placed in a goblet that is suspended in liquid nitrogen with the top portion of the goblet approximately 1 cm above the surface) for 1-15 min before being plunged into liquid nitrogen. The warming procedure is similar to that for slow-cooled embryos except that the straw is held at room temperature (20-24 • C) for 10 s before being placed in a 35 • C water bath for 20 s prior to shaking (like a thermometer) to mix columns before wiping dry and loading into a 0.25-mL ET gun for transfer.The ease of this technique decreases handling time after warming, eliminates the use of a microscope and expedites transfers. A small study using this procedure yielded a 50% pregnancy rate (n = 8) compared with a pregnancy rate of 38.5% with conventional direct transfer (n = 8) of in vivo-derived Brahman embryos (Pryor et al. 2007) . In 1997, a large field trial was conducted comparing vitrification and slow controlled cooling and freezing of Day-7 in vivo-derived Bos taurus embryos (van Wagtendonk-de Leeuw et al. 1997) . That study demonstrated that vitrification could be performed under field conditions without significantly reducing pregnancy rates (vitrify/in-straw dilution post-warming 44.5% v. slow controlled freezing in glycerol with three-step removal after thaw 45.0%). Recently, IVP embryos were collected from Friesian donors in New Zealand and either transferred fresh or vitrified then warmed and transferred, resulting in pregnancy rates of 53% (59/112) and 50% (65/130), respectively (Frers et al. 2009 ). In that study, the authors used the CryoLogic vitrification method (Biogenics, Napa, CA, USA), which is more labour intensive than in-straw warming/dilution and transfer, with the same (if not better) pregnancy rates. Currently, the authors are working with forskolin (a lipolytic agent) in conjunction with vitrification to determine whether combining these two strategies will enhance the cryotolerance of both in vivo-produced and IVP embryos.
Some advantages of vitrification include, but are not limited to, the simplicity of the technique, the ability to vitrify hardto-freeze embryos, time efficiency (4 min per embryo) and the use of inexpensive equipment (a programmable freezer is not required). Two of the disadvantages of vitrification are the high concentrations of cryoprotectants, which may be toxic to the embryo, especially when embryos are held for longer periods of time than specified, and the need for attention to detail. Although there are many vitrification procedures (Vajta 2000; Lindemans et al. 2004) , time constraints may become an issue if a large number of embryos is to be cryopreserved by one technician (e.g. 40 embryos would take 160 min to vitrify v. 72 min for slow controlled freezing).
Vitrification: cost effectiveness
From the standpoint of media, the Bovine Vitrification Kit (BionicheAnimal Health) will allow you to cryopreserve up to 30 embryos at US$2.50 per embryo, compared with 200 embryos at a cost of US$0.08 per embryo using Ethylene Glycol Plus (50 mL pouch; Bioniche Animal Health). However, this cost is trivial if pregnancy rates from hard-to-freeze donor embryos can be increased over conventional direct transfer methods. For smallvolume operations, the cost of a programmable freezer can be as much as US$6500 depending on the model and, under these circumstances, vitrification could have much to offer. Some vitrification procedures require special equipment that can be purchased from companies such as Biogenics (CryoLogic vitrification; US$2560) or Minitube ofAmerica (Vit Set; US$1615.00) depending on the carrier (fibre hook or open-pulled straw).
Conclusions
The ability for the practitioner to apply new technology depends on a system for data procurement, analytical ease of use and the resourcing areas for application. Advances in biotechnology have allowed developments within economical guidelines in the ET industry. The practicality of a technique may not always provide optimum results, but refinements over time may (e.g. the use of ethylene glycol for direct transfer). In addition, practical applications of new research may produce initially unforeseen applications, benefiting both the ET practitioner and the livestock industry.
